FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($2.95) per share for the year, down from their previous forecast of ($2.84). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.81) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2024 earnings at ($0.86) EPS and FY2025 earnings at ($3.76) EPS.

A number of other research firms also recently weighed in on FDMT. Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Leerink Partners reiterated an “outperform” rating and issued a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Chardan Capital restated a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $47.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $8.83 on Monday. 4D Molecular Therapeutics has a fifty-two week low of $7.32 and a fifty-two week high of $36.25. The firm has a market capitalization of $408.21 million, a P/E ratio of -3.10 and a beta of 2.82. The company’s 50 day simple moving average is $10.30 and its 200 day simple moving average is $17.03.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently made changes to their positions in FDMT. Allspring Global Investments Holdings LLC lifted its holdings in shares of 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after purchasing an additional 3,026 shares in the last quarter. nVerses Capital LLC acquired a new position in 4D Molecular Therapeutics during the 3rd quarter worth approximately $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $57,000. Quest Partners LLC lifted its position in shares of 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.